


Cicaprost

Cat. No.:	HY-19583
CAS No.:	94079-80-8
Molecular Formula:	C ₂₂ H ₃₀ O ₅
Molecular Weight:	374.47
Target:	Prostaglandin Receptor
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Cicaprost (ZK 96480) is a prostacyclin receptor (IP) agonist. Cicaprost causes a concentration-dependent relaxation of the artery with an EC ₅₀ of 5.8 nM [1]									
IC₅₀ & Target	IP									
In Vitro	<p>Cicaprost significantly reduces proliferation of human pulmonary artery smooth muscle cells (HPASMC) stimulated by fetal bovine serum (FBS). Cicaprost displays marked antiproliferative activity at 30 nM^[2].</p> <p>Cicaprost stimulates [³H]cyclic AMP production with EC₅₀ values of 1.5-22 nM, and stimulates [³H]inositol phosphate production (EC₅₀ values 49-457 nM) in all but the SK-N-SH cells^[3].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay^[2]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>HPASMC</td> </tr> <tr> <td>Concentration:</td> <td>10 pM, 100 pM, 1 nM, 10 nM, 100 nM, 1 μM, and 10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td></td> </tr> <tr> <td>Result:</td> <td>Dose-dependently inhibited proliferation with an EC₅₀ of 24.1 nM.</td> </tr> </table>		Cell Line:	HPASMC	Concentration:	10 pM, 100 pM, 1 nM, 10 nM, 100 nM, 1 μM, and 10 μM	Incubation Time:		Result:	Dose-dependently inhibited proliferation with an EC ₅₀ of 24.1 nM.
Cell Line:	HPASMC									
Concentration:	10 pM, 100 pM, 1 nM, 10 nM, 100 nM, 1 μM, and 10 μM									
Incubation Time:										
Result:	Dose-dependently inhibited proliferation with an EC ₅₀ of 24.1 nM.									
In Vivo	<p>Cicaprost alters pain perception and inflammatory response in mice lacking prostacyclin receptor. Intravenous injection of Cicaprost (1 μg/kg) causes hypotension of -30 mm Hg in anaesthetized wild-type mice^[4].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Wild-type (+/+) and IP^{-/-} mice^[4]</td> </tr> <tr> <td>Dosage:</td> <td>1 μg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection</td> </tr> <tr> <td>Result:</td> <td>Caused hypotension of ~30 mm Hg in anaesthetized wild-type mice, whereas there was no change in blood pressure in IP-deficient mice even at 10 μg/kg.</td> </tr> </table>		Animal Model:	Wild-type (+/+) and IP ^{-/-} mice ^[4]	Dosage:	1 μg/kg	Administration:	Intravenous injection	Result:	Caused hypotension of ~30 mm Hg in anaesthetized wild-type mice, whereas there was no change in blood pressure in IP-deficient mice even at 10 μg/kg.
Animal Model:	Wild-type (+/+) and IP ^{-/-} mice ^[4]									
Dosage:	1 μg/kg									
Administration:	Intravenous injection									
Result:	Caused hypotension of ~30 mm Hg in anaesthetized wild-type mice, whereas there was no change in blood pressure in IP-deficient mice even at 10 μg/kg.									

REFERENCES

- [1]. Nicole Ferko, et al. NO synergism with cicaprost in the canine pulmonary artery. *BioPharm Journal ONLINE* 2:2 (1998).
- [2]. Lucie H Clapp, et al. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. *Am J Respir Cell Mol Biol.* 2002 Feb;26(2):194-201.
- [3]. Kevin B S Chow, et al. Protein kinase A-dependent coupling of mouse prostacyclin receptors to Gi is cell-type dependent. *Eur J Pharmacol.* 2003 Aug 1;474(1):7-13.
- [4]. T Murata, et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. *Nature.* 1997 Aug 14;388(6643):678-82.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA